New lung fibrosis drug SV001 enters first human safety trial

NCT ID NCT06267183

Recruiting now Disease control Sponsor: Shanghai Synvida Biotechnology Co.,Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This early-phase study tests a new drug called SV001 in 53 healthy Chinese adults to see if it is safe and how the body processes it. Participants receive a single dose of SV001 or a placebo. The goal is to check for side effects and measure drug levels in the blood. This is a first step toward possibly treating idiopathic pulmonary fibrosis, a condition that scars the lungs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SV001
What this could lead to: If this early safety trial succeeds, it could pave the way for a new treatment to control idiopathic pulmonary fibrosis, a serious lung disease.
What could go wrong: This is a very early Phase 1 trial in healthy volunteers, not patients. It only tests safety and dosing, not whether the drug works. Many drugs fail at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC PULMONARY FIBROSIS

Contacts and locations

Locations

Shanghai Xuhui District Central Hospital
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.